antiviral drug active in the treatment of acquired immunodeficiency syndrome (recommended human dose, 100 mg every 4 hr while awake), was evaluated for mutagenic and carcinogenic potential in a battery of short-term in vitro and in vivo assays and in lifetime studies in mice and rats. In L5178Y mouse lymphoma cells (tk + '~ locus), a weak positive result was obtained only at the highest concentrations tested (4000 to 5000 /xg/ml) in the absence of metabolic activation. In the presence of metabolic activation, the drug was weakly mutagenic at concentrations of 1000 /xg/ml and higher. Following 24 hr treatment in the absence of metabolic activation, ZDV was moderately mutagenic at concentrations up to 600 /xg/ml; dose-related structural chromosomal alterations were seen at concentrations of 3 /ig/ml and higher in cultured human lymphocytes. Such effects were not noted at the two lowest concentrations tested, 0.3 and 1 /xg/ml, and BALB/C-3T3 cells were transformed at concentrations of 0.5 /xg/ml and higher. No effects were seen in the Ames Salmonella plate incorporation and preincubation modification assays (possibly due to bacteriocidal activity of ZDV at low concentrations) at concentrations ranging from 0.01 to 10 /xg/plate or in a singledose intravenous bone marrow cytogenetic assay in CD rats. In multidose micronucleus studies, increases in micronucleated erythrocytes were seen in mice at doses of 100 to 1000 mg/kg/day. Similar results were seen in rats and mice after 4 or 7 days of dosing at 500 mg/kg/day. In carcinogenicity bioassays, adjusted doses of 20, 30, or 40 mg/kg/day and 80, 220, and 300 mg/kg/day were given to CD-I mice and CD rats, respectively, for up to 22 months in mice and 24 months in rats. ZDV caused a macrocytic, normochromic anemia in both species. No evidence of carcinogenicity was seen in male mice or rats. In female mice, five malignant and two benign vaginal epithelial neoplasms occurred in animals given 40 mg/kg/day. A single benign vaginal epithelial tumor was seen in a mouse given 30 mg/kg/day. In rats, two malignant vaginal epithelial neoplasms were seen in animals given 300 mg/kg/day. In a 7-day study in mice, ZDV was shown to be devoid of estrogenic activity. In an oral pharmacokinetics study, the AUC was 17 and 140 /xg/ml • hr in female mice and rats given 40 or 300 mg/kg of ZDV, respectively. In contrast, the average steady-state concentration in humans at the recommended daily dose is 0.62 /xg/ml. Twenty-four hour urine concentrations were 1245 and 4417 0272-0590/96 $18.00 1 Copyright O 1996 by the Society of Toxicology. All rights of reproduction in any form reserved.
/xg/ml in female mice and rats given 40 or 300 mg/kg of ZDV, respectively. These values were approximately 26-and 136-fold higher than the human urine concentration at the recommended daily dose. In a one-to three-day study with intravenously administered sodium fluoroscein in rats and mice, retrograde flow of urine into the vagina was demonstrated. In a subsequent lifetime carcinogenicity bioassay in mice in which ZDV was given intravaginally at concentrations of 5 or 20 mg ZDV/ml in saline, 13 vaginal squamous cell carcinomas were seen at the highest concentration tested. It was concluded that the vaginal tumors seen in the oral carcinogenicity studies were the result of chronic local exposure of the vaginal epithelium to high urine concentrations of ZDV.
C 1996 Soddy of Toxicology
Because patients take zidovudine (ZDV) chronically, its mutagenic and carcinogenic potential was assessed in a battery of short-term in vitro and in vivo assays and in lifetime bioassays in mice and rats.
MATERIALS AND METHODS
The chemicals and methods employed in the genetic toxicology assays conducted with ZDV in prokaryotic and eukaryotic systems and in whole animals are described briefly below. , Chemicals. The free base of ZDV was used for all studies. Trifluorothymidine (TFT, Burroughs Wellcome Co.) was used for mutant selection at the tk locus in the L5178Y/lk + '~ mouse lymphoma assay (MLA). Phytohemagglutinin (PHA, Burroughs Wellcome Co.) was employed to stimulate division of human lymphocytes. Colcemid (G1BCO) was used to arrest cells in metaphase for cytogenetic analysis.
The following positive control compounds were used: Hycanthone methanesulfonate (Hyc; a generous gift from Sterling Winthrop) and 2-acetylaminofluorene (2-AAF; Aldnch) for the MLA; ethyl methanesulfonate (EMS; Eastman Organic) for the human lymphocyte cytogenetic assay; 3-methylcholanthrene (MCA; IITRI) for the cell transformation study; cyclophosphamide (CP; Koch-Light Ltd.) for the rat cytogenetic study.
Metabolic activation. Metabolic activation for the microbial and mouse lymphoma assays was as described by Ames et at. (1975) and Clive el al. (1979) , respectively
In vitro and in vivo assays. 1. Salmonella reverse mutation assays were performed according to the procedures described by Ames et al. (1975) and Yahagi et al. (1977) . ZDV was tested in a modification of the plate incorporation assay at concentrations ranging from 0.01 to 10 /xg/plate. both with and without exogenous S9 metabolic activation. Additional testing was performed in the preincubation modification assay over the same concentration range, both with and without exogenous S9 metabolic activation. Testing of higher concentrations was precluded due to ZDV's bacteriocidal activity. Strains TA1535, 1537 TA1535, , 1538 , and 100 were used in both assays.
2. The L5178Y/f* + '~ -• tk~'~ MLA was conducted according to the procedures of Turner et al. (1984) . Separate cultures, each containing 6 x 10 6 recently cleansed tk*'~ -3.7.2C cells, were treated with concentrations of ZDV ranging from 1000 to 5000 /ig/ml for 4 hr in the absence and presence of Aroclor-induced S9. In addition, duplicate solvent controls and single positive controls were set up for each metabolic activation condition. Following removal of the test or control compounds, each culture was monitored daily for cell number and maintained in exponential growth for 2 days' expression. At the end of this expression period, 3 x 10* cells from solvent and positive control cultures and cultures treated with concentrations of ZDV were cloned in the presence of the selective agent, TFT, for tk~'m utant number, an additional 600 cells from these same cultures were cloned under nonselective conditions for viable count (VC). Following incubation for 11 days, colonies on vehicle control (VC) plates were enumerated with an Artek Model 880 colony counter and the colonies on TFT plates were enumerated at each of 17 uniformly spaced size settings for total mutant counts and colony size distribution.
An additional experiment in the absence of S9 was performed as above, except that exposures to ZDV concentrations were 25 to 600 /tg/ml and the length of exposure was 24 instead of 4.0 hr.
3. The in vitro cytogenetics assay was performed according to the procedures of Evans and O'Riordan (1975) . Peripheral blood lymphocytes from a healthy donor were treated in vitro with single doses of ZDV at 11 concentrations between 0.3 and 1000 /xg/ml for 48 hi in the absence of exogenous metabolic activation. Cells were cultured in RPMI 1640 medium supplemented by 15% fetal bovine serum (FBS), 100 units penicillin/ml, 100 fig streptomycin/ml, 2 iw L-glutamine, and 2.0 ml of phytohemaglutinin for each 100 ml total volume. The 9.4-ml aliquots of medium and 0.6 ml of heparinized blood were added to T-25 flasks. Flasks were gently mixed, gassed with COj, and placed at 37°C. After 48 hr of culture, cells were treated by the test compound at various concentrations (determined previously by a test for cytotoxicity) for 48 hr in the absence of S9. Appropriate solvent and positive controls were included. Three hours prior to harvest, cells were blocked in mitosis by the addition of Colcemid (0.2 figl ml). At the end of the Colcemid treatment, cells were harvested (including hypotonic treatment) and fixed. Slides of the cells were prepared, stained (Giemsa), and scored under a light microscope for chromosome aberrations.
4. In a mammalian in vitro cell transformation assay the methods described by Kakunaga (1973) and Reznikoff et al. (1973) were used. Briefly, BALB/C-3T3 cells were treated with ZDV 24 hr after inoculation into petri plates. Based on preliminary cytotoxicity results, cells were exposed to concentrations of ZDV ranging from 0.05 to 5.0 /ig/ml for 72 hr, separate cultures were exposed to 3-MCA as a positive control. Following this treatment, medium was removed and the cells were replenished with fresh medium without test chemical every 4-7 days for approximately 4 weeks of incubation. At the end of the incubation period, the plates were fixed and stained and type III foci were scored. Cytotoxicity of the tested concentrations was determined in a separate parallel experiment.
5. The rat bone marrow cytogenetic assay was conducted according to the procedures outlined by Kilian et al. (1977) . Six groups of four male and four female CD rats were given a single iv dose of a vehicle control and 12 groups of the same size were given single iv doses of 37.5, 75, 150, and 300 mg/kg of ZDV. Four males and four females from the vehicle control group and from each test compound dose group were euthanized at 6, 24, and 48 hr after dosing. In addition, four male and four female rats were given a single ip dose of 40 mg/kg cyclophosphamide and were euthanized 24 hr after dosing.
6. A series of four oral, multiple-dose micronucleus assays in mice and rats (Oleson and Getman, 1990) were also conducted. These studies were conducted to provide data for comparison to results obtained with anti-HTV drugs under development in the author's company. Groups of 5-7 Charles River CD-I male mice' were given 0, 100, 250, 500, or 1000 mg/kg/day of ZDV suspended in 1 % sodium carboxymethylcellulose daily, by gavage, for 4 weeks in the first study. Five separate groups of 7 CD-I male mice each were given 0, 10, 15, 20, or 22.5 mg/kg/day of cyclophosphamide for 2 days and served as positive controls. In the second study, 3 groups of 5 males each were given 0, 100, or 1000 mg/kg/day of ZDV, daily by gavage, for 4 weeks. In study 3, 4 groups of 5 male CD-I mice each were given 0 or 500 mg/kg/day of ZDV, daily, by gavage for 4 or 7 days, and in study 4, 2 groups of 5 male CD rats each were given 0 or 500 mg/kg/day of ZDV for 7 days. At the termination of dosing in studies 1 and 2, all animals were euthanized and peripheral blood smears were prepared from each animal for the analysis of micronucleus frequencies. At the terminal euthanization in studies 3 and 4, peripheral blood smears were prepared from the mice in study 3 and bone marrow from all animals (studies 3 and 4) was removed from the femurs by flushing with FBS. The marrow/FBS mixture was centrifuged to concentrate the marrow cells and bone marrow smears were prepared from the suspended pellets. All micronucleus evaluations were performed blind on coded slides and the following parameters were calculated: percentage micronucleated polychromatic erythrocytes (PCEs) of total PCEs scored, percentage micronucleated normochromatic erythrocytes (NCEs), and percentage PCEs of total erythrocytes counted. The means and standard deviations for these parameters were calculated for each control-and ZDV-treated group. A statistical evaluation to determine significance of each measured parameter was not performed.
Carcinogenicity bioassays. Three groups of 60 male and 60 female CD rats (see Footnote 1) (42 days of age) and three groups of 100 male and 100 female CD-1 mice (see Footnote 1) (49 days of age) were singly housed in suspended wire cages and provided food 2 and tap water ad libitum. In both studies ZDV was administered once daily as a suspension in 0 5% methylcellulose. In 3-, 6-, and 12-month studies in rats the total daily dose was given in two equal portions approximately 6 hr apart. For the carcinogenicity studies it was decided to dose once daily in order to cut down on the daily handling of the animals. Three-month oral dose range-finding studies were subsequently conducted in the rat and mouse using once-daily dosing in order to select doses for the carcinogenicity studies. In both dose range-finding studies anemia was the major toxicity noted. Based on these results, starting dose levels of 80, 220, and 600 mg/ kg/day were given to rats in the carcinogenicity study. The presence of anemia on Day 91 prompted the lowering of the high dose to 450 mg/kg/ day. Progression of the anemia at the high dose was noted on Day 278 and there was a further reduction of the dose to 300 mg/kg/day, where it remained for the duration of the study. In mice, the starting dose levels (selected based on the results of the preliminary 90-day dose range-finding study) were 30, 60, and 120 mg/kg/day. When anemia was seen on Day 91 in mid-and high-dose animals, the doses were lowered to 20, 30, and 40 mg/kg/day, respectively, where they remained for the rest of the study. Two separate groups of 60 male and 60 female rats and two groups of 85 male and 85 female mice were left untreated (environmental controls) or were given 0.5% methylcellulose once daily (vehicle controls). In both bioassays animals were monitored daily for signs of toxicity. In both species body weights and food consumption were measured weekly, changing to biweekly at 6 months and monthly at 1 year. The animals in both studies were examined weekly for the presence of externally visible masses. Twenty-five to 40 mice per group were used only for hematologic and drug plasma concentration determinations (no tissues saved for histopathology [WBC] , WBC differential, and platelets) were determined from 6 randomly selected mice/ sex/group euthanized on Days 91, 179, 269, 359, and at term, and from 10 randomly selected rats/sex/group on Days 91, 182, 269, 360, and at term. The same rats were used for hematology determinations throughout the study unless a death occurred, at which time a different rat was randomly selected as a replacement. ZDV plasma concentrations were measured by HPLC (Good etal, 1990) in mice (3/sex/group) 30 min after dosing on Days 5, 90, 180, 270, and at term. ZDV plasma concentrations were measured in rats (3/sex/group) on Days 6, 93, 178, 272, and at term Each study was terminated at 24 months or when survival reached 25% in the low-dose or vehicle control group. Males and females could be terminated at separate time points based on these survival guidelines. The study was terminated at 19 and 22 months for male and female mice, respectively, and at 22 and 24 months for female and male rats, respectively. All mice and rats that were found dead, euthanized for humane reasons, or euthanized at term were examined grossly A wide variety of tissues were taken, fixed in 10% neutral buffered formalin, and processed for light microscopic examination. Tissues from all rats and mice in the environmental and vehicle control and high-dose groups were examined microscopically. In addition, the vagina was examined from all rats and mice in the low-and intermediatedose groups. For both species, all gross lesions suggestive of a neoplasm in the low-and intermediate-dose groups were examined microscopically.
Four-day oral pharmacokinetic study in rats and mice. This study was conducted to determine the pharmacokjnetic profile and urine concentrations after oral administration of ZDV. Three groups of 27 male and 27 female CD rats (see Footnote 1) were given ZDV orally once daily for 4 days at doses of 80, 220, or 300 mg/kg/day. Similarly, three groups of 54 male and 54 female CD-I (see Footnote I) mice were given ZDV orally once daily for 4 days at doses of 20, 30, or 40 mg/kg/day. On Day 3, 24-hr urine samples were collected from mice and rats in metabolism cages. On Day 4, plasma samples were obtained from the posterior vena cava from anesthetized rats and mice at 5, 15, and 30 min and 1, 2, 4, 6, 8, and 24 hr after dosing. ZDV concentrations in plasma and urine were measured by HPLC (Good et al., 1990) .
Seven-day bioassay for the detection of potential estrogenic activity of ZDV. In order to determine if ZDV possessed estrogenic activity, a study was conducted using methods developed by Thigpen et al. (1987) for the detection of estrogenic activity in rodent diets. Groups of immature, 15-dayold female CD-1 mice were given 20 or 40 mg/kg/day of ZDV suspended in 0.5% methylcellulose orally for 7 days. Three additional groups (15 females each) were fed diets containing 0, 4, or 6 ppb of diethylstilbestrol (DES) daily for 7 days. At the end of dosing all animals were weighed and euthanized and dieir uteri were removed and weighed. The uterine:body weight ratio (U:BW) was calculated for all animals and the group means were compared.
One-to three-day iv dose range-finding study in rats and mice given sodium fluoroscein iv. To explore the possible pathogenesis of vaginal tumors observed in rats and mice, a study was conducted to determine if urine could flow in a retrograde fashion from the urethral orifice into the vagina of rats. Two groups of five female CD-I (see Footnote 1) mice and one group of five female CD rats (see Footnote 1) were given 5 mg/kg of sodium fluoroscein as a single iv dose. An additional group of five female CD-I mice were given 5 mg/kg/day of sodium fluoroscein iv for 3 days. The fluoroscein was administered as a I mg/ml solution in 0.9% normal saline at a dose volume of 5 ml/kg. Animals were euthanized 1 hr after the last dose and the mucosal surface of the vagina was examined in a darkened room with an ultraviolet lamp for the presence of urine containing fluoroscein.
Intravaginal carcinogenicity study in mice. Two groups of 50 female CD-1 mice (see Footnote 1) (48 days of age) were singly housed in suspended wire cages and provided food (see Footnote 2) and tap water ad libitum. ZDV was administered intravaginally twice daily (doses approximately 6 hr apart) as a solution in 0.9% saline. Dosing volume was 0.4 ml (0.2 ml X 2) daily. Dose levels were 5 and 20 mg of ZDV/ml. The highest dose tested was selected to exaggerate the urine concentrations of ZDV observed in the 4-day oral pharmacokinetic study in rats and mice. Two additional groups of 50 female CD-I mice each were either left untreated (environmental control) or were given 0.4 ml (0.2 ml x 2) of 0.9% saline intravaginally daily and served as vehicle controls. Two satellite groups of six mice each were given ZDV intravaginally at the doses shown above and were used to determine ZDV plasma levels on Study Day 5. ZDV plasma levels were also determined for six animals each in groups 3 and 4 at the terminal euthanization on Day 574. Animals were monitored daily for signs of toxicity. Body weights were measured weekly, changing to biweekly at 6 months and monthly at 1 year. Mice were examined weekly for the presence of externally visible masses. The study was to be terminated at 24 months or when survival reached 25% in the low-dose or vehicle control group. All mice found dead, euthanized for humane reasons or euthanized at term were examined grossly. A wide variety of tissues were taken, fixed in 10% neutral buffered formalin, and processed for light microscopic examination. Only the vagina (4 levels) and the cervix were examined microscopically from all groups.
RESULTS

Genetic Toxicology Tests
No evidence of mutagenicity (with or without metabolic activation) was observed in the Ames Salmonella assay at concentrations up to 10 /xg/plate, the maximum concentration that could be tested because of the bacteriocidal activity of ZDV. In the mutagenicity assay in L5178Y/r/: +/~ mouse lymphoma cells ZDV was weakly positive only at the highest concentrations tested (4000 to 5000 /xg/ml) in the absence of metabolic activation. In the presence of metabolic activation, the drug was weakly mutagenic at concentrations of 1000 /xg/ml and higher. Following 24-hr treatment in the absence of metabolic activation, ZDV was moderately mutagenic at all concentrations up to 600 ^g/ml. In an in vitro cytogenetic study performed in human lymphocytes, ZDV induced dose-related structural chromosomal alterations at concentrations of 3 /xg/ml and higher. Such effects were not noted at the two lowest concentrations tested, 0.3 and 1 /ig/ ml. In an in vitro mammalian cell transformation assay, ZDV was positive at concentrations of 0.5 /xg/ml and higher. In an in vivo cytogenetic study in rats given a single iv injection of ZDV at doses of 37.5 to 300 mg/kg, there were no treatment-related structural or numerical chromosomal alterations even though ZDV plasma levels were as high as 453 /ig/ml 5 min after dosing.
Significant dose-related increases in the percentage micronucleated erythrocytes in the peripheral blood were observed in mice treated with ZDV at doses of 100, 250, 500, and 1000 mg/kg/day for 4 weeks. These results were confirmed in a second study in which mice were treated for 4 weeks at dose levels of 100 and 1000 mg/kg/day. Bone marrow micronucleus frequencies were also elevated in mice and rats treated with ZDV at 500 mg/kg/day for 4 (mice only) or 7 days. Intravenous 4-day ZDV administration also gave significant micronucleus responses (Oleson and Getman, 1990) .
Carcinogenicity Bioassays
Treatment with ZDV did not affect survival in either sex of either species. Survival analysis, as evaluated by log-rank test in SAS, is presented in Figs, la and lb and 2a and 2b. With the exception of male mice given 40 mg/kg/day, survival at 18 months in both species was 50% or greater. No deaths or morbidity in mice or rats that was thought to be related to treatment with ZDV occurred. The most common cause of death or morbidity in the mouse study was amyloidosis, a common finding in aging CD-I mice. For rats, spontaneous pituitary adenomas and chronic progressive nephrosis were common causes of death and morbidity.
Treatment-related clinical signs were not seen in mice, but in rats the incidence of hair staining on various parts of the body was increased at 220 or 300 mg/kg/day. Body weight was unaffected by treatment in either sex of either species.
As shown in Tables 1 and 2 , hematocrit (HCT), hemoglobin (Hb), and total erythrocyte count (RBC) were decreased and mean corpuscular volume (MCV), mean corpuscular hemoglobin (MCH), and red cell distribution width (RDW) were increased for both species on Day 91. Mean corpuscular hemoglobin concentration (MCHC) was unaltered by treatment. Because of concerns that the anemia would adversely affect long-term survival, the mouse mid and high doses were reduced to 30 and 40 mg/kg/day, respectively, while the 30 mg/kg/day dose was lowered to 20 mg/kg/day. No further dose changes were made. For rats, the 600 mg/kg/ day dose was reduced to 450 mg/kg/day on Day 91. On Day 269 further progression of the anemia was noted, and the 450 mg/kg/day dose was lowered to 300 mg/kg/day, where it remained for the duration of the bioassay. At study termination, anemia was still evident in both rats and mice. Changes in the erythron were also seen in animals given 80 and 220 mg/kg/day. Treatment had no effect on WBC or on platelets in either species.
No treatment-related gross lesions were noted in mice or rats. Histopathologically, seven late-appearing vaginal epithelial cell tumors were seen in mice given 40 mg/kg/day. These included five well-differentiated squamous cell carcinomas, one squamous cell papilloma, and one squamous polyp (Table 3 ). In one mouse given 30 mg/kg/day a single squamous cell papilloma was seen, whereas no vaginal tumors occurred in mice given 20 mg/kg/day. In rats, two lateappearing squamous cell carcinomas were noted at 300 mg/ kg/day, but no vaginal tumors occurred at 80 or 220 mg/kg/ day (Table 3 ). The neoplasms in both species occurred in the distal vagina, just anterior to the vulva. There was no evidence of metastases from malignant tumors. In mice, the earliest vaginal tumor seen was in an animal found dead on Day 579. Five of the seven tumors in mice receiving 40 mg/ kg/day were found in animals killed at the study's scheduled termination. In rats, one tumor was observed in an animal found dead on Day 615 and the other in a rat killed at the scheduled termination of the bioassay on Day 668. Squamous cell hyperplasia of the vaginal epithelium was seen in all groups of mice, including the controls. Moderate to severe hyperplasia, however, was increased in incidence in mice given 30 or 40 mg/kg/day of ZDV (Table 4) . Squamous cell hyperplasia was not noted in rats.
Treatment of rats and mice with ZDV did not affect the incidence of any other benign or malignant tumor in any tissue or organ examined. As shown in Tables 5 and 6 , there were no differences between the groups of control and treated rats of both sexes or male mouse groups in the number of benign rumor-bearing animals (TBAs), malignant TBAs, or total TBAs. For female mice, no differences were seen for benign, malignant, or total TBAs between the control, low-, and intermediate-dose groups. The slight excess noted in malignant TBAs in the high-dose group was due to the presence of five vaginal squamous cell carcinomas. The results of ZDV plasma level analyses in mice and rats are shown in Table 7 . In mice given 40 mg/kg/day mean peak ZDV plasma concentration at term was 25 fig/m\ . In rats given 300 mg/kg/day the mean peak ZDV plasma concentration was 108 pg/ml at term. In separate 4-day oral dose range-finding studies, area-under-the-concentration time curve (AUC) and 24-hr urine concentrations were determined for rats and mice given doses of ZDV identical to those used in the bioassays. The results of these analyses are presented in Table 8 . In mice given 40 mg/kg/day, the AUC for ZDV after a single oral dose was 15 and 17 fig • ml • hr for males and females, respectively. In female and male rats given 300 mg/kg/day, the AUC was 140 and 132 //g • ml • hr, respectively. Analysis of 24-hour urine samples revealed concentrations up to 1245 ^g/ml in mice given 40 mg/kg/day and 4417 /xg/ml in rats given 300 mg/kg/day (Table 9 ).
In the 7-day mouse bioassay performed to determine if ZDV possessed estrogenic activity, U:BW ratios for the groups given 20 or 40 mg/kg/day of ZDV were unaffected by treatment. In contrast, in animals given DES, there was a dose-related increase in U:BW ratio. On the basis of these results, it was concluded that ZDV does not possess estrogenic activity.
Since the urethra in mice and rats dose not empty into the vagina, a further study was conducted to determine if urine could flow in a retrograde fashion from the urethral orifice into the vagina. In female CD-I mice and CD rats given sodium fluoroscein iv, fluorescence was noted on the mucosal surface of the vagina in animals given one or three doses of the compound. These findings demonstrated that retrograde flow of urine into the vagina does occur in both mice and rats.
In the intravaginal carcinogenicity study in mice, 13 vaginal squamous cell carcinomas were seen in mice given 0.4 ml of a 20 mg/mJ solution of ZDV daily intravaginally for 2 years. Two squamous cell carcinomas of the vagina occurred at the lowest concentration tested (5 mg/ml). Vaginal epithelial cell tumors were not seen in either control group. The incidence of these findings is shown in Table 10 . The earliest a tumor was seen was after 15 months of dosing in a high-dose animal euthanized for humane reasons. In addition to the vaginal neoplasms, focal vaginal epithelial cell dysplasia was noted in one low-dose and six high-dose mice. The mean peak ZDV concentration seen 45 min after the first dose on Day 574 was 1.1 /zg/ml (Table 11) .
DISCUSSION
Genetic toxicology studies demonstrated that ZDV (a) was weakly mutagenic in mouse lymphoma cells, (b) induced cell transformation in vitro, and (c) was clastogenic in vitro and in vivo following multiple but not single doses in rats and mice. In lifetime carcinogenicity bioassays in mice and rats, ZDV induced neoplasms in females only, and these were limited to the vaginal epithelium. In view of the genetic toxicology findings, this limited carcinogenic effect of ZDV is surprising but not unprecedented. Tennant et al. (1987) evaluated the concordance between the results of rodent carcinogenicity studies conducted by the NTP and found that the results of short-term (in vitro) tests agreed with the carcinogenicity bioassays only 60% of the time. It is evident, therefore, that short-term tests do not necessarily predict for the outcome of lifetime studies in rodents.
Zidovudine was carcinogenic to the vaginal epithelium in mice given adjusted dose levels of 30 and 40 mg/kg/day and rats given an adjusted dose level of 300 mg/kg/day. The incidence of vaginal tumors was higher in mice than rats (eight tumors in mice vs two in rats). Since the metabolism of ZDV in rats and mice is similar, the reason for this difference in species sensitivity is not known.
Spontaneous tumors of the vaginal epithelium are rare in rodents (Munoz et ai, 1979; Baba and von Haam, 1976) , and reports of chemically induced vaginal tumors are also uncommon. Of 222 chemicals evaluated for carcinogenicity in rats and mice in the National Toxicology Program (NTP), none induced tumors in the vagina (Ashby and Tennant, 1988) . It should be pointed out, however, that the vagina is estradiol 3-benzoate, and 17/3-estradiol, which accounted for majority of the reports of chemically induced vaginal neoplasms in the literature (Highman et al., 1980; McLachlan, 1977; McLachlan et al., 1980 McLachlan et al., , 1982 Newbold and McLachlan, 1982; Walker, 1983 Walker, , 1984 Baggs et al, 1980; Miller era/., 1982) . The pathogenesis of the ZDV-induced vaginal tumors in the mouse and rat is unknown. Since chemically induced vaginal tumors are rare and have only been associated with estrogen treatment, a hormonal mechanism was considered. Review of the pathophysiologic findings in these rodent bioassays with ZDV does not, however, reveal any alterations that would suggest that the tumors were hormonally mediated. Further, data from two-generation reproduction-fertility and perinatal-postnatal ZDV studies in rats (Greene et ai, 1996) also do not reveal any functional disturbances that would suggest that ZDV possesses any intrinsic hormonal activity. In addition, in a 6-month oral toxicity study (Ayers et ai, 1996) in cynomolgus monkeys, ZDV had no effect on menstrual cycles. Finally, ZDV was negative in a standard mouse bioassay that is sensitive to estrogenic effects. It would seem unlikely, therefore, that the treatment-related vaginal neoplasms in the current studies were related to hyperestrinism. Note. EC, environmental control; VC. vehicle control. We believe that the vaginal tumors resulted from lifetime local exposure of the highly replicative vaginal epithelium to high local concentrations of ZDV. This conclusion is based on the following information:
a. The results of the carcinogenicity bioassays in mice and rats reported in this paper which showed that the effect of ZDV was sex-and site-specific. Treatment-related neoplastic changes were in the vaginal epithelium in the distal vagina, just anterior to the vulva.
b. The estrus cycle in the mouse and rat is only 4-5 days long, resulting in a high rate of vaginal epithelial cell turnover, with the vaginal epithelium being completely replaced within this 4-to 5-day period.
c. Although the urethra in the mouse and rat does not empty into the vagina, but instead discharges at the base of the vulva, we have shown that there is retrograde flow of urine into the region of the vagina where the tumors were found in the carcinogenicity studies.
d. Very little ZDV-glucuronide is formed in rats or mice, so that greater than 90% of an administered dose of ZDV is excreted by the kidneys as unchanged ZDV. The results of the 3-day dose range-finding study described earlier demonstrated that high urinary concentrations of ZDV occur in both species. Interestingly, ZDV urine concentrations were higher in females at all dose levels than in males.
e. Intravaginal administration in a lifetime carcinogenicity study with ZDV resulted in a high incidence of vaginal squamous cell carcinoma. These tumors developed as a result of the local action of ZDV, as the mean peak ZDV plasma concentration at the highest dose tested in this study was one-tenth the peak plasma concentrations seen at the NOEL for vaginal tumors in the oral carcinogenicity study in mice (1.1 /xg/ml at highest dose tested intravaginally vs 11 fj.g/m\ at 20 mg/kg/day po).
We conclude, therefore, that prolonged local exposure of the rapidly dividing rodent vaginal epithelium to high concentrations of ZDV resulted in alterations leading to the formation of tumors in the oral carcinogenicity studies with ZDV in mice and rats. Why drug-related tumors were not seen in other tissues with high replication rates, such as the gastrointestinal tract, is uncertain.
